Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

被引：0

作者：

Llovet, Josep M.

Singal, Amit G.

Villanueva, Augusto

Finn, Richard S.

Kudo, Masatoshi

Galle, Peter R.

Wang, Chunxiao

Widau, Ryan C.

Gugel, Elena Gonzalez

Zhu, Andrew X.

机构：

[1] Icahn Sch Med Mt Sinai, Div Liver Dis, Tisch Canc Inst, New York, NY 10029 USA

[2] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[3] Icahn Sch Med Mt Sina, Dept Med, Div Liver Dis, Mt Sinai, NY USA

[4] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA

[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[6] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Eli Lilly, Indianapolis, IN USA

[9] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4146

引用

页数：2

共 50 条

[21] Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
Masatoshi Kudo
Takuji Okusaka
Kenta Motomura
Izumi Ohno
Manabu Morimoto
Satoru Seo
Yoshiyuki Wada
Shinpei Sato
Tatsuya Yamashita
Masayuki Furukawa
Takeshi Aramaki
Seijin Nadano
Kazuyoshi Ohkawa
Hirofumi Fujii
Toshihiro Kudo
Junji Furuse
Hiroki Takai
Gosuke Homma
Reigetsu Yoshikawa
Andrew X. Zhu
Journal of Gastroenterology, 2020, 55 : 627 - 639
[22] Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
Yen, Chia-Jui
Kudo, Masatoshi
Lim, Ho-Yeong
Hsu, Chih-Hung
Vogel, Arndt
Brandi, Giovanni
Cheng, Rebecca
Nitu, Ioana Simona
Abada, Paolo
Hsu, Yanzhi
Zhu, Andrew X.
Kang, Yoon-Koo
LIVER CANCER, 2020, 9 (04) : 440 - 454
[23] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Kelley, R. K.
El-Khoueiry, A. B.
Meyer, T.
Rimassa, L.
Merle, P.
Chan, S. L.
Tran, A.
Parnis, F.
Tam, V. C.
Cattan, S.
Markby, D. W.
Clary, D. O.
Cheng, A-L.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2018, 29
[24] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
Kudo, Masatoshi
Okusaka, Takuji
Motomura, Kenta
Ohno, Izumi
Morimoto, Manabu
Seo, Satoru
Wada, Yoshiyuki
Sato, Shinpei
Yamashita, Tatsuya
Furukawa, Masayuki
Aramaki, Takeshi
Nadano, Seijin
Ohkawa, Kazuyoshi
Fujii, Hirofumi
Kudo, Toshihiro
Furuse, Junji
Takai, Hiroki
Homma, Gosuke
Yoshikawa, Reigetsu
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[25] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
Galle, Peter
Kudo, Masatoshi
Llovet, Josep M.
Finn, Richard
Karwal, Mark
Denis, Pezet
Kim, Tae-You
Yang, Tsai-Sheng
Zagonel, Vittorina
Tomasek, Jiri
Phelip, Jean-Marc
Touchefeu, Yann
Koh, Su-Jin
Stirnimann, Guido
Wang, Chunxiao
Widau, Ryan
Hsu, Yanzhi
Abada, Paolo B.
Zhu, Andrew
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E46 - E46
[26] Overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): A real-world retrospective study.
Hennenfent, Kristin L.
Girvan, Allicia C.
Chaudhry, Aafia
Abada, Paolo
Sheffield, Kristin
Herren, Catherine K.
Raju, Aditya
Farrelly, Eileen
Bowman, Lee
Landsman-Blurnberg, Pamela
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2
Galle, Peter R.
Kudo, Masatoshi
Llovet, Josep M.
Finn, Richard S.
Karwal, Mark
Pezet, Denis
Kim, Tae-You
Yang, Tsai-Sheng
Zagonel, Vittorina
Tomasek, Jiri
Phelip, Jean Marc
Touchefeu, Yann
Koh, Su-Jin
Stirnimann, Guido
Wang, Chunxiao
Ogburn, Kenyon
Abada, Paolo
Widau, Ryan C.
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[28] Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Kelley, Robin Kate
Meyer, Tim
Rimassa, Lorenza
Merle, Philippe
Park, Joong-Won
Yau, Thomas
Chan, Stephen L.
Blanc, Jean-Frederic
Tam, Vincent C.
Tran, Albert
Dadduzio, Vincenzo
Markby, David W.
Kaldate, Rajesh
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Abou-Alfa, Ghassan K.
CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4795 - 4804
[29] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).
Shao, Guoliang
Bai, Yuxian
Chen, Xiaoming
Gu, Shanzhi
Gu, Kangsheng
Yuan, Xianglin
Widau, Ryan C.
Zhang, Wanli
Zhang, Qiang
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16081 - E16081
[30] Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
Finn, R. S.
Qin, S-K.
Galle, P. R.
Wang, C.
Ogburn, K. D.
Widau, R.
Zhu, A. X.
ANNALS OF ONCOLOGY, 2020, 31 : S702 - S702

← 1 2 3 4 5 →